Featured Publications
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Lee A, Wong S, Chai L, Lee S, Lee M, Muthiah M, Tay S, Teo C, Tan B, Chan Y, Sundar R, Soon Y. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. The BMJ 2022, 376: e068632. PMID: 35236664, PMCID: PMC8889026, DOI: 10.1136/bmj-2021-068632.Peer-Reviewed Original ResearchConceptsImmune mediated inflammatory disorderOrgan transplant recipientsEfficacy of COVID-19 vaccinesTransplant recipientsRisk of biasImmunocompromised patientsSolid cancersInflammatory disordersImmunocompetent controlsHaematological cancersSeroconversion ratesMeta-analysisCOVID-19 vaccineMRNA vaccinesVaccine doseSystematic reviewCOVID-19 mRNA vaccinesWHO International Clinical Trials Registry PlatformCentral Register of Controlled TrialsVaccine non-respondersAssociated with seroconversionInternational Clinical Trials Registry PlatformProspective observational studyRegister of Controlled TrialsLow risk of bias
2023
Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups
Wong N, Yap D, Ong R, Zhao J, Chan Y, Tey J, Sundar R, Lim J, Dawood S. Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups. Annals Of Oncology 2023 PMID: 37871699, DOI: 10.1016/j.annonc.2023.10.122.Peer-Reviewed Original ResearchTreatment of physician's choiceIndividual patient dataOral SERDsMetastatic breast cancerPFS benefitKaplan MeierBreast cancerEstimate time-to-event outcomesHER2- metastatic breast cancerESR1 mutation statusIndividual patient data meta-analysisOverall populationAdvanced breast cancerMeta-analysisMutant subgroupESR1 mutationsEndocrine therapyMutation statusRandomised controlled trialsOverall cohortPooled analysisDrug classesPFSPhysician's choicePreferred Reporting ItemsEfficacy of oral selective estrogen receptor degraders (SERD)s in the treatment of estrogen receptor positive (ER+), HER2-negative metastatic breast cancer (MBC): A stratified analysis of the ESR1 wild type (wt) and mutant (mt) subgroups.
Zhao J, Wong Zhun Hong N, Yap D, Ong R, Sundar R, Lim J, Dawood S. Efficacy of oral selective estrogen receptor degraders (SERD)s in the treatment of estrogen receptor positive (ER+), HER2-negative metastatic breast cancer (MBC): A stratified analysis of the ESR1 wild type (wt) and mutant (mt) subgroups. Journal Of Clinical Oncology 2023, 41: 1096-1096. DOI: 10.1200/jco.2023.41.16_suppl.1096.Peer-Reviewed Original ResearchProgression free survival benefitTreatment of physician's choiceProgression free survivalMetastatic breast cancerEndocrine therapyESR1 mutationsOverall cohortEstrogen receptorKaplan MeierEstimate time-to-event outcomesHER2-negative metastatic breast cancerOral selective estrogen receptor degraderHER2- metastatic breast cancerSurvival dataTreatment of estrogen receptorSelective estrogen receptor degraderOverall populationCompare survival outcomesIPD meta-analysisMeta-analysisEstrogen receptor degraderOral SERDsPFS differenceCompared to ETFree survival
2022
Obstructive sleep apnea and the incidence and mortality of gastrointestinal cancers: a systematic review and meta-analysis of 5,120,837 participants
Teo Y, Tan B, Tan N, Yap D, Chai Y, Teo Y, Sia C, Sundar R, Tan E, See A, Toh S. Obstructive sleep apnea and the incidence and mortality of gastrointestinal cancers: a systematic review and meta-analysis of 5,120,837 participants. Journal Of Gastrointestinal Oncology 2022, 0: 0-0. PMID: 36636076, PMCID: PMC9830329, DOI: 10.21037/jgo-22-153.Peer-Reviewed Original ResearchObstructive sleep apneaAssociation of obstructive sleep apneaSleep apneaGastrointestinal cancerCancer incidenceColorectal cancerMeta-analysisPancreatic cancerFollow-upObstructive sleep apnea screeningYears of median follow-upColorectal cancer screening guidelinesLong-term follow-upIncreased risk of colorectal cancerIncreased incidence of colorectal cancerRisk of colorectal cancerIncidence of colorectal cancerMedian follow-upPancreatic cancer incidenceCancer screening guidelinesSleep apnea screeningIncidence of gastrointestinal cancerMortality of gastrointestinal cancersSystematic reviewHigh-risk individualsFirst-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis
Fong K, Zhao J, Sultana R, Lee J, Lee S, Chan S, Yau T, Tai D, Sundar R, Too C. First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis. Liver Cancer 2022, 12: 7-18. PMID: 36872922, PMCID: PMC9982345, DOI: 10.1159/000526639.Peer-Reviewed Original ResearchAdvanced hepatocellular carcinomaProgression-free survivalFirst-line systemic therapyBarcelona Clinic Liver CancerNetwork meta-analysisOverall survivalStandard of careAlpha-fetoproteinHazard ratioOS benefitSystemic therapyFirst-lineHepatocellular carcinomaFirst-line combination therapyRandom-effects network meta-analysisCombination of atezolizumabInhibitor monoclonal antibodiesFirst-line therapyCochrane Controlled Register of TrialsMeta-analysisKaplan-Meier curvesIndividual patient-level dataCochrane Controlled RegisterRegister of TrialsExtrahepatic spreadBooster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis
Mai A, Lee A, Tay R, Shapiro L, Thakkar A, Halmos B, Grinshpun A, Herishanu Y, Benjamini O, Tadmor T, Shroff R, LaFleur B, Bhattacharya D, Peng S, Tey J, Lee S, Chai L, Soon Y, Sundar R, Lee M. Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. European Journal Of Cancer 2022, 172: 65-75. PMID: 35753213, PMCID: PMC9163022, DOI: 10.1016/j.ejca.2022.05.029.Peer-Reviewed Original ResearchConceptsIndividual patient data meta-analysisPatient data meta-analysisSolid cancersBooster doseNon-respondersData meta-analysisHaematological cancersMeta-analysisAntibody titresBooster dose of COVID-19 vaccineAssociated with increased durationIncreased risk of severe diseaseResponse to booster vaccinationAge of patientsRisk of severe diseaseVaccine non-respondersDose of COVID-19 vaccineSystematic reviewJoanna Briggs Institute Critical Appraisal ChecklistGastrointestinal cancer patientsCOVID-19 vaccine booster doseReduced vaccine immunogenicityVaccine booster doseImproved seroconversionCritical Appraisal ChecklistAssociation of obstructive sleep apnea and nocturnal hypoxemia with all-cancer incidence and mortality: a systematic review and meta-analysis.
Tan B, Teo Y, Tan N, Yap D, Sundar R, Lee C, See A, Toh S. Association of obstructive sleep apnea and nocturnal hypoxemia with all-cancer incidence and mortality: a systematic review and meta-analysis. Journal Of Clinical Sleep Medicine 2022, 18: 1427-1440. PMID: 34755597, PMCID: PMC9059590, DOI: 10.5664/jcsm.9772.Peer-Reviewed Original ResearchConceptsAssociation of obstructive sleep apneaObstructive sleep apneaAll-cancer riskAll-cancer incidenceSevere nocturnal hypoxemiaNocturnal hypoxemiaSleep apneaAll-cancer mortalityModerate obstructive sleep apneaNo/mild OSASevere obstructive sleep apneaObstructive sleep apnea diagnosisObstructive sleep apnea treatmentOxygen desaturation indexMeta-analysisNewcastle-Ottawa ScaleSystematic reviewRandom-effects meta-analysesQuality of evidenceArousal indexDesaturation indexNormoxemic patientsRandomized studyHypoxemiaEvaluated study biasUNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies
Tan D, Lim W, Yong J, Ng C, Muthiah M, Tan E, Xiao J, Lim S, Pin Tang A, Pan X, Kabir T, Bonney G, Sundar R, Syn N, Kim B, Dan Y, Noureddin M, Loomba R, Huang D. UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies. Clinical Gastroenterology And Hepatology 2022, 21: 1475-1484. PMID: 35181565, DOI: 10.1016/j.cgh.2022.02.018.Peer-Reviewed Original ResearchConceptsUNOS-DS criteriaHepatocellular carcinoma recurrenceUNOS-DSDown-stagingOverall survivalLiver transplantationHepatocellular carcinomaMilan criteriaPost-LTLiver transplantation of hepatocellular carcinomaTransplantation of hepatocellular carcinomaAbstractText Label="RESULTS">WeAdult HCC patientsBaseline tumor burdenPost-LT outcomesDown-staging treatmentTumor burdenHCC patientsEmbase databasesPooled analysisPatientsIndividual participant dataRecurrenceClinical validationMeta-analysisPrevention of Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis
Peng S, Ying A, Chan N, Sundar R, Soon Y, Bandla A. Prevention of Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Frontiers In Oncology 2022, 12: 731223. PMID: 35186722, PMCID: PMC8853097, DOI: 10.3389/fonc.2022.731223.Peer-Reviewed Original ResearchOxaliplatin-induced peripheral neuropathyNon-pharmacological interventionsChronic oxaliplatin-induced peripheral neuropathyMeta-analysisSystematic reviewPrevent oxaliplatin-induced peripheral neuropathyGrading of RecommendationsPreventive measuresPooled risk ratioQuality of lifeRandomized controlled trialsPrimary outcome measureRandom-effects modelDatabases PubMed-MEDLINENetwork meta-analysisPreventive interventionsOutcome measuresNo interventionPubMed-MedlinePeripheral neuropathyClinical impactRisk ratioControlled trialsCancer patientsConfidence intervalsA Systematic Review and Meta-Analysis of the Effectiveness of Neuroprotectants for Paclitaxel-Induced Peripheral Neuropathy
Leen A, Yap D, Teo C, Tan B, Molassiotis A, Ishiguro H, Fan S, Sundar R, Soon Y, Bandla A. A Systematic Review and Meta-Analysis of the Effectiveness of Neuroprotectants for Paclitaxel-Induced Peripheral Neuropathy. Frontiers In Oncology 2022, 11: 763229. PMID: 35070969, PMCID: PMC8766304, DOI: 10.3389/fonc.2021.763229.Peer-Reviewed Original ResearchPaclitaxel-induced peripheral neuropathyPeripheral neuropathyTreatment arm compared to controlsMeta-analysisPooled resultsNeuroprotective interventionsSide effects of paclitaxelEffects of paclitaxelDisabling side effectsEffect of neuroprotectionNon-pharmacological interventionsNon-pharmacological trialsRelevant controlled trialsNon-pharmacological approachesRandom-effects modelEffective prevention strategiesBiomedical Literature DatabasePrimary outcomePharmacological trialsModerate heterogeneityPrevention strategiesPharmacological interventionsSystematic reviewLiterature databasesIntervention
2021
Cryotherapy for Prevention of Taxane-Induced Peripheral Neuropathy: A Meta-Analysis
Jia J, Guo Y, Sundar R, Bandla A, Hao Z. Cryotherapy for Prevention of Taxane-Induced Peripheral Neuropathy: A Meta-Analysis. Frontiers In Oncology 2021, 11: 781812. PMID: 34912720, PMCID: PMC8667340, DOI: 10.3389/fonc.2021.781812.Peer-Reviewed Original ResearchTaxane-induced peripheral neuropathyCommon Terminology Criteria for Adverse EventsChemotherapy-induced peripheral neuropathyPeripheral neuropathyDose reductionMeta-analysisSensory neuropathyIncidence of taxane-induced peripheral neuropathyIncidence of sensory neuropathyPrevent chemotherapy-induced peripheral neuropathyLimits chemotherapy doseEfficacy of cryotherapyIncidence of motorAssociated with reduced incidenceQuality of lifeNerve conduction studiesMeta-Analysis softwareReduce patients' qualityGynecological cancer therapyNeuropathy questionnaireChemotherapy doseClinical guidelinesMotor neuropathyAdverse eventsClinical evidenceSmall bowel adenocarcinoma in Crohn’s disease: a systematic review and meta-analysis of the prevalence, manifestation, histopathology, and outcomes
Chin Y, Jain S, Lee M, Ng C, Lin S, Mai A, Muthiah M, Foo F, Sundar R, Ong D, Leow W, Leong R, Chan W. Small bowel adenocarcinoma in Crohn’s disease: a systematic review and meta-analysis of the prevalence, manifestation, histopathology, and outcomes. International Journal Of Colorectal Disease 2021, 37: 239-250. PMID: 34704127, DOI: 10.1007/s00384-021-04050-1.Peer-Reviewed Original ResearchConceptsMolecular analysis findingsCrohn's diseaseOverall survivalClinical presentationBowel adenocarcinomaCD patientsInflammatory bowel disease patientsMeta-analysisSmall bowel adenocarcinomaAssociated with Crohn's diseaseConclusionOur meta-analysisMethodsElectronic databases MedlineStatistically significant increaseEpithelial dysplasiaAbdominal painMismatch repair deficiencyKRAS mutationsRadiological featuresHistopathological findingsGenetic mutationsPatientsRepair deficiencyResultsIn totalDisease patientsHistopathology
2020
Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review
Cheong C, Nistala K, Ng C, Syn N, Chang H, Sundar R, Yang S, Chong C. Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review. Journal Of Gastrointestinal Oncology 2020, 11: 847-857. PMID: 33209481, PMCID: PMC7657836, DOI: 10.21037/jgo-20-220.Peer-Reviewed Original ResearchLocally advanced colon cancerAdvanced colon cancerR0 resection rateDisease-free survivalNeoadjuvant chemotherapyColon cancerNeoadjuvant therapyRandomized controlled trialsOverall survivalResection rateAdjuvant chemotherapyChina Knowledge Resource Integrated DatabaseSurvival benefit of neoadjuvant chemotherapyBenefit of neoadjuvant chemotherapyRisk of peri-operative complicationsObservational studyObservational study of patientsAdverse effects of chemotherapyPeri-operative complicationsPotential survival benefitMeta-analysisEffects of chemotherapyStudy of patientsFOxTROT trialUpfront operationMetformin and colorectal cancer: a systematic review, meta-analysis and meta-regression
Ng C, Jiang A, Toh E, Ng C, Ong Z, Peng S, Tham H, Sundar R, Chong C, Khoo C. Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression. International Journal Of Colorectal Disease 2020, 35: 1501-1512. PMID: 32592092, DOI: 10.1007/s00384-020-03676-x.Peer-Reviewed Original ResearchConceptsColorectal adenomasCancer incidenceImprove colorectal cancer outcomesNon-metformin usersColorectal cancerIncidence of colorectal adenomasMeta-analysisMetformin usersIncidence of colorectal cancerHazard ratioRisk ratioReducing colorectal adenomasColorectal cancer outcomesCRC-specific survivalCancer survival outcomesEffect of metformin useMetformin useSurvival outcomesAdvanced adenomasDiet-only treatmentDerSimonian and LairdCancer outcomesOverall survivalMethodsA database searchConclusionThis meta-analysis